Search

Displaying results 6531 - 6540 of 10000 in total
  1. Drug

    Human Embryonic Stem Cell-derived M Cell

    go.drugbank.com/drugs/DB15734
    Investigational

    IMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. … However, the difference comes with IMRCs displaying a higher quality of consistency, having stronger immunomodulatory and anti-fibrotic functions, and being stronger in potential treatment of lung injury

  2. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors.

  3. Drug

    Mepiprazole

    go.drugbank.com/drugs/DB09197
    Experimental

    Mepiprazole mediates a weak inhibitory action on the uptake of 5-HT on hypothalamic neurons [A7816]. Mepiprazole is marketed in Spain for the treatment of anxiety neuroses. … Clinical studies of mepiprazole including patients with irritable bowel syndrome (IBS) were conducted and the results showed some beneficial effects of mepiprazole in relieving IBS symptoms in certain

  4. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary

  5. Drug

    Arbekacin

    go.drugbank.com/drugs/DB06696
    Investigational

    An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).

  6. Drug

    Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16711
    ApprovedInvestigational

    It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  7. Drug

    Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10287
    ApprovedInvestigational

    It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  8. Drug

    Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10288
    ApprovedInvestigational

    It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  9. Drug

    Streptococcus pneumoniae type 18C capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10290
    ApprovedInvestigational

    It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  10. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    )[L12675] with an expected completion in December 2020. … [L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906